REQUEST A DEMO
Total
USD $0.00
Search more companies

Samchundang Pharm. Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing | Medicinal and Botanical Manufacturing
Full name: Samchundang Pharm. Co.,Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

The Company is a Korea-based pharmaceutical company. The Company offers ethical products under product names of Clamox, SCD Ranitidine, Loxofen, Facle and Barotase. Its over-the-counter (OTC) products include Narista-S nasal spray, Cardiotonic pills and Iris eye drop. The Company also has started its health food business offering supplement food for diabetic patients and special health food for liver disease patients. The Company s production facility is located in HyangNam Pharmaceutical Industrial Park, which is comprised of the departments of Production, Factory control, and Quality control. The Company was established on 29 December 1943. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on 4 October 2000.

Headquarters
904-1 Sangshin-Ri, Hyangnahm-Myun, Hwaseong-Gun
Hwaseong; Gyeonggi; Postal Code: 445-922

Contact Details: Purchase the Samchundang Pharm. Co.,Ltd. report to view the information.

Website: http://www.scd.co.kr

Basic Information
Total Employees:
Purchase the Samchundang Pharm. Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Samchundang Pharm. Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Samchundang Pharm. Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Samchundang Pharm. Co.,Ltd. report to view the information.
Incorporation Date:
December 29, 1943
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
President
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Auditor
Ownership Details
Purchase this report to view the information.
8%
Subsidiaries
수인약품(주)
74%
Optus Pharmaceutical Co., Ltd.
41.87%
삼천당제약(주)
31%
Company Performance
Financial values in the chart are available after Samchundang Pharm. Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
6.3%
Total operating revenue
6.33%
Operating profit (EBIT)
-9.59%
EBITDA
10.3%
Net Profit (Loss) for the Period
6.68%
Total assets
7.43%
Total equity
-0.39%
Operating Profit Margin (ROS)
-0.3%
Net Profit Margin
0.01%
Return on Equity (ROE)
0.08%
Debt to Equity Ratio
3.04%
Quick Ratio
-1.47%
Cash Ratio
-1.14%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?